Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Hereditary Disease Foundation (HDF) conference 2022 – Day 3

Read updates from clinical trials and scientific research on Huntington’s disease from Day 3 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Rachel Harding, Dr Leora Fox, Dr Sarah Hernandez, and Dr Jeff CarrollSeptember 01, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Hereditary Disease Foundation (HDF) conference 2022 – Day 2

Read updates from clinical trials and scientific research on Huntington’s disease from Day 2 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Leora Fox, Dr Rachel Harding, and Dr Sarah HernandezAugust 31, 2022

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Hereditary Disease Foundation (HDF) conference 2022 – Day 1

Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022

Dr Rachel Harding and Dr Sarah HernandezAugust 31, 2022

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials

After receiving a high dose of uniQure’s gene therapy for Huntington’s disease, a few patients experienced serious side effects, but are now recovering. HDBuzz explores what this means for the experimental huntingtin-lowering drug, AMT-130.

Dr Sarah Hernandez and Dr Rachel HardingAugust 29, 2022

Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam

Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam

HDBuzz is saddened to share the news that the VIBRANT-HD trial of the oral huntingtin-lowering drug, branaplam, has been temporarily suspended for the safety of participants.

Dr Leora FoxAugust 08, 2022

Updates from uniQure about their gene therapy for Huntington's disease

Updates from uniQure about their gene therapy for Huntington's disease

uniQure is conducting safety trials of the first gene therapy for HD. A recent press release provided a 1 year update on the first group of 10 people who underwent surgery to receive this experimental drug. Let’s talk more about what it means.

Dr Leora Fox and Dr Rachel HardingJuly 11, 2022

Huntington’s disease therapeutics conference 2022 - Day 2

Huntington’s disease therapeutics conference 2022 - Day 2

Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2022

Dr Sarah Hernandez, Dr Leora Fox, Dr Rachel Harding, and Joel StantonJune 21, 2022

Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.

Artificial intelligence to save the day? How clever computers are helping us understand Huntington’s disease.

Scientists at IBM and the CHDI Foundation have used artificial intelligence to analyse datasets from Huntington’s disease observational trials to model progression of the disease. They hope their findings will help improve clinical trial design.

Dr Rachel HardingJune 21, 2022

Huntington’s disease therapeutics conference 2022 - Day 1

Huntington’s disease therapeutics conference 2022 - Day 1

Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2022

Dr Rachel Harding, Dr Leora Fox, Dr Sarah Hernandez, and Joel StantonJune 20, 2022

A new roadmap to track Huntington’s disease progression

A new roadmap to track Huntington’s disease progression

Researchers have updated the system that classifies Huntington’s disease progression. Tracking progression in 4 stages will make clinical trial screening and data interpretation easier and faster, and pave the way for pre-symptomatic trials.

Dr Sarah HernandezJune 15, 2022

Revisiting vitamin therapy for HD

Revisiting vitamin therapy for HD

A small clinical trial of high-dose biotin and thiamine for treating HD is being planned in Spain. This trial is based on research that links HD to another neurodegenerative disease called biotin-thiamine responsive basal ganglia disease (BTBGD).

Makenna May and Dr Leora FoxMay 19, 2022

Donate

Please consider making a donation if you value the services that HDBuzz provides. We want HDBuzz to be sustainable so that we can continue to report unbiased science to the HD community.

With your support, we can ensure the continuity of our services. Nothing is expected, but everything is appreciated and sustains what we do at HDBuzz. Please consider giving what you're able. More information...